Top

Published in:

01-03-2010 | Review Paper

Alzheimer’s Disease and Neuronal Network Activity

Authors: Marc Gleichmann, Mark P. Mattson

Published in: NeuroMolecular Medicine | Issue 1/2010

Abstract

The amyloid β-peptide theory of Alzheimer’s Disease has helped to advance our understanding of the disease tremendously. A new area of research focuses on the changes in neuronal network activity that take place and may contribute to the clinical and pathological picture of Alzheimer’s Disease. An apparent symptom of altered neuronal network activity in Alzheimer’s Disease is an increased frequency in epileptic seizures that is observed both in human patients and in mouse models of Alzheimer’s Disease. A root cause for altered network activity may be amyloid β itself by its ability to alter synaptic (glutamatergic) transmission and to impair the induction of long-term potentiation. It is on this aspect of Alzheimer’s Disease research that the current issue of NeuroMolecular Medicine will focus. Reviews will discuss the basic research and clinical aspects of the issue such as the effects of amyloid β on synaptic transmission and neuronal networks, as well as the changes in functional MRI activation patterns observed in early stages of Alzheimer’s Disease and the frequency and relevance of epileptic seizures in Alzheimer’s Disease patients.

Bezprozvanny, I., & Mattson, M. P. (2008). Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends in Neurosciences, 31, 454–463.CrossRefPubMed

Chan, S. L., Mayne, M., Holden, C. P., Geiger, J. D., & Mattson, M. P. (2000). Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. Journal of Biological Chemistry, 275, 18195–18200.CrossRefPubMed

Cheung, K. H., Shineman, D., Müller, M., Cárdenas, C., Mei, L., Yang, J., et al. (2008). Mechanism of Ca2+ disruption in Alzheimer’s disease by presenilin regulation of InsP3 receptor channel gating. Neuron, 58, 871–883.CrossRefPubMed

Forman, M. S., Mufson, E. J., Leurgans, S., Pratico, D., Joyce, S., Leight, S., et al. (2007). Cortical biochemistry in MCI and Alzheimer disease: Lack of correlation with clinical diagnosis. Neurology, 68, 757–763.CrossRefPubMed

Furukawa, K., Barger, S. W., Blalock, E. M., & Mattson, M. P. (1996). Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature, 379, 74–78.CrossRefPubMed

Guo, Q., Sopher, B. L., Furukawa, K., Pham, D. G., Robinson, N., Martin, G. M., et al. (1997). Alzheimer’s presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. Journal of Neuroscience, 17, 4212–4222.PubMed

Halagappa, V. K., Guo, Z., Pearson, M., Matsuoka, Y., Cutler, R. G., Laferla, F. M., et al. (2007). Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer’s disease. Neurobiology of Diseases, 26, 212–220.CrossRef

Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., et al. (2003). APP processing and synaptic function. Neuron, 37, 925–937.CrossRefPubMed

Kuchibhotla, K. V., Goldman, S. T., Lattarulo, C. R., Wu, H. Y., Hyman, B. T., & Bacskai, B. J. (2008). Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron, 59, 214–225.CrossRefPubMed

Kumar-Singh, S., Dewachter, I., Moechars, D., Lübke, U., De Jonghe, C., Ceuterick, C., et al. (2000). Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiology of Diseases, 7, 9–22.CrossRef

LaFerla, F. M., Tinkle, B. T., Bieberich, C. J., Haudenschild, C. C., & Jay, G. (1995). The Alzheimer’s A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nature Genetics, 9, 21–30.CrossRefPubMed

Lalonde, R., Dumont, M., Staufenbiel, M., & Strazielle, C. (2005). Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behavioural Brain Research, 157, 91–98.CrossRefPubMed

Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009). Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature, 457, 1128–1132.CrossRefPubMed

Loerch, P. M., Lu, T., Dakin, K. A., Vann, J. M., Isaacs, A., Geula, C., et al. (2008). Evolution of the aging brain transcriptome and synaptic regulation. PLoS One, 3, e3329.CrossRefPubMed

Lopez, J. R., Lyckman, A., Oddo, S., Laferla, F. M., Querfurth, H. W., & Shtifman, A. (2008). Increased intraneuronal resting [Ca2+] in adult Alzheimer’s disease mice. Journal of Neurochemistry, 105, 262–271.CrossRefPubMed

Markesbery, W. R., & Lovell, M. A. (2007). Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Archives of Neurology, 64, 954–956.CrossRefPubMed

Mattson, M. P. (2004a). Pathways towards and away from Alzheimer’s disease. Nature, 430, 631–639.CrossRefPubMed

Mattson, M. P. (2004b). Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Annals of the New York Academy of Sciences, 1012, 37–50.CrossRefPubMed

Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., & Rydel, R. E. (1992). beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Journal of Neuroscience, 12, 376–389.PubMed

Mesulam, M. M. (2000). A plasticity-based theory of the pathogenesis of Alzheimer’s disease. Annals of the New York Academy of Sciences, 924, 42–52.PubMedCrossRef

Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., et al. (2008). Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature, 451, 720–724.CrossRefPubMed

Moechars, D., Lorent, K., & Van Leuven, F. (1999). Premature death in transgenic mice that overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and apoptosis. Neuroscience, 91, 819–830.CrossRefPubMed

Nelson, O., Tu, H., Lei, T., Bentahir, M., de Strooper, B., & Bezprozvanny, I. (2007). Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. Journal of Clinical Investigation, 117, 1230–1239.CrossRefPubMed

Oddo, S., Caccamo, A., Cheng, D., Jouleh, B., Torp, R., & LaFerla, F. M. (2007). Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. Journal of Neurochemistry, 102, 1053–1063.CrossRefPubMed

Oddo, S., Caccamo, A., Cheng, D., & Laferla, F. M. (2008a). Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathology, 19, 421–430.CrossRefPubMed

Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B. P., & LaFerla, F. M. (2003a). Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiology of Aging, 24, 1063–1070.CrossRefPubMed

Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., et al. (2003b). Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron, 39, 409–421.CrossRefPubMed

Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., et al. (2006). Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. Journal of Biological Chemistry, 281, 1599–1604.CrossRefPubMed

Oddo, S., Caccamo, A., Tseng, B., Cheng, D., Vasilevko, V., Cribbs, D. H., et al. (2008b). Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. Journal of Neuroscience, 28, 12163–12175.CrossRefPubMed

Palop, J. J., Chin, J., & Mucke, L. (2006). A network dysfunction perspective on neurodegenerative diseases. Nature, 443, 768–773.CrossRefPubMed

Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., et al. (2007). Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron, 55, 697–711.CrossRefPubMed

Palop, J. J., & Mucke, L. (2009). Epilepsy and cognitive impairments in Alzheimer disease. Archives of Neurology, 66, 435–440.CrossRefPubMed

Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nature Medicine, 14, 837–842.CrossRefPubMed

Sperling, R. A., Laviolette, P. S., O’Keefe, K., O’Brien, J., Rentz, D. M., Pihlajamaki, M., et al. (2009). Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron, 63, 178–188.CrossRefPubMed

Tu, H., Nelson, O., Bezprozvanny, A., Wang, Z., Lee, S. F., Hao, Y. H., et al. (2006). Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer’s disease-linked mutations. Cell, 126, 981–993.CrossRefPubMed

Zuccato, C., & Cattaneo, E. (2009). Brain-derived neurotrophic factor in neurodegenerative diseases. Nature Reviews: Neurology, 5, 311–322.CrossRefPubMed

Title: Alzheimer’s Disease and Neuronal Network Activity
Authors: Marc Gleichmann
Mark P. Mattson
Publication date: 01-03-2010
Publisher: Humana Press Inc
Published in: NeuroMolecular Medicine / Issue 1/2010
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-009-8100-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Alzheimer’s Disease and Neuronal Network Activity

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Synaptic Depression and Aberrant Excitatory Network Activity in Alzheimer’s Disease: Two Faces of the Same Coin?

Epileptic Seizures in AD Patients

Functional Alterations in Memory Networks in Early Alzheimer’s Disease

Alzheimer’s Disease Amyloid β-Protein and Synaptic Function

Translin-Associated Factor X Gene (TSNAX) may be Associated with Female major Depressive Disorder in the Japanese Population

An Overview of APP Processing Enzymes and Products